Online inquiry

IVTScrip™ mRNA-Anti-IGHE, 47H4(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ496MR)

This product GTTS-WQ496MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IGHE gene. The antibody can be applied in Urticaria research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NC_000014.9
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3497
UniProt ID P01854
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IGHE, 47H4(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ496MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4452MR IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-901608
GTTS-WQ5103MR IVTScrip™ mRNA-Anti-CD52, Campath-1H(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Campath-1H
GTTS-WQ13648MR IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA RB4v1.2
GTTS-WQ12565MR IVTScrip™ mRNA-Anti-Felcat NGF, NV-02(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA NV-02
GTTS-WQ14562MR IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA aCD1919
GTTS-WQ13033MR IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA Peg-IFNA2 R23
GTTS-WQ4901MR IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BYM338
GTTS-WQ5260MR IVTScrip™ mRNA-Anti-S, CB-6(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CB-6
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW